









市场行情
/
股票
/
nasdaq-prta
/

Prothena Corporation PLC

PRTA

9.540USD

-0.150-1.55%

收盘 12/26, 16:00（美东）报价延迟15分钟

513.54M总市值

亏损市盈率 TTM



Prothena Corporation PLC

9.540

-0.150-1.55%

概览公司财务分析

概览

公司

财务

分析

关于 Prothena Corporation PLC 公司

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Prothena Corporation PLC简介



公司代码PRTA

公司名称Prothena Corporation PLC

上市日期Dec 21, 2012

CEOKinney (Gene G)

员工数量163

证券类型Ordinary Share

年结日Dec 21

公司地址77 Sir John Rogerson's Quay, Block C

城市DUBLIN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Ireland

邮编D02 VK60

电话35312362500

网址https://www.prothena.com/

公司代码PRTA

上市日期Dec 21, 2012

CEOKinney (Gene G)

Prothena Corporation PLC公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Brandon S. Smith

Chief Operating Officer

130.00K

Dr. Wagner M. Zago, Ph.D.

Chief Scientific Officer

85.00K

Dr. Dennis J. Selkoe, M.D.

Independent Director

4.21K

Mr. Richard T. Collier

Independent Director

1.22K

Dr. Lars G. Ekman, M.D., Ph.D.

Chairman Emeritus

243.00

Mr. Daniel G. Welch

Independent Chairman of the Board

Mr. Shane M. Cooke

Independent Director

Ms. Karin L. Walker, CPA

Chief Accounting Officer

Ms. Paula K. Cobb

Independent Director

Ms. Helen S. Kim

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Brandon S. Smith

Chief Operating Officer

130.00K

Dr. Wagner M. Zago, Ph.D.

Chief Scientific Officer

85.00K

Dr. Dennis J. Selkoe, M.D.

Independent Director

4.21K

Mr. Richard T. Collier

Independent Director

1.22K

Dr. Lars G. Ekman, M.D., Ph.D.

Chairman Emeritus

243.00

Mr. Daniel G. Welch

Independent Chairman of the Board

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Fidelity Management & Research Company LLC

14.68%

Scully (William P)

9.81%

Fennell (Todd W.)

8.35%

BlackRock Institutional Trust Company, N.A.

5.51%

The Vanguard Group, Inc.

3.81%

其他

57.84%

持股股东

占比

Fidelity Management & Research Company LLC

14.68%

Scully (William P)

9.81%

Fennell (Todd W.)

8.35%

BlackRock Institutional Trust Company, N.A.

5.51%

The Vanguard Group, Inc.

3.81%

其他

57.84%

股东类型

持股股东

占比

Investment Advisor

35.22%

Hedge Fund

23.86%

Individual Investor

19.39%

Investment Advisor/Hedge Fund

15.99%

Research Firm

4.34%

Pension Fund

0.19%

Bank and Trust

0.16%

Sovereign Wealth Fund

0.11%

Venture Capital

0.03%

其他

0.71%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

450

41.85M

77.74%

-15.20M

2025Q2

460

51.33M

95.35%

-19.91M

2025Q1

472

64.29M

119.45%

-7.39M

2024Q4

479

65.24M

121.19%

+239.99K

2024Q3

476

59.39M

110.43%

-5.39M

2024Q2

479

58.48M

108.76%

-4.67M

2024Q1

472

60.86M

113.29%

-264.94K

2023Q4

474

56.64M

105.77%

-2.21M

2023Q3

476

55.90M

104.65%

-1.73M

2023Q2

475

55.02M

104.46%

-3.12M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Fidelity Management & Research Company LLC

7.90M

14.68%

-40.18K

-0.51%

Jun 30, 2025

Scully (William P)

5.35M

9.94%

-255.90K

-4.56%

Jun 30, 2025

Fennell (Todd W.)

4.35M

8.08%

-239.96K

-5.23%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.12M

5.8%

-162.75K

-4.95%

Jun 30, 2025

The Vanguard Group, Inc.

2.17M

4.03%

+906.96K

+71.95%

Jun 30, 2025

Armistice Capital LLC

2.24M

4.15%

+40.00K

+1.82%

Jun 30, 2025

Adar1 Capital Management LLC

3.38M

6.27%

+3.38M

Jun 30, 2025

Palo Alto Investors LP

1.27M

2.37%

-384.98K

-23.20%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Virtus LifeSci Biotech Clinical Trials ETF

1.44%

iShares Neuroscience and Healthcare ETF

0.78%

Invesco NASDAQ Future Gen 200 ETF

0.7%

Federated Hermes MDT Small Cap Core ETF

0.62%

ALPS Medical Breakthroughs ETF

0.24%

ProShares Ultra Nasdaq Biotechnology

0.07%

Invesco Nasdaq Biotechnology ETF

0.06%

Avantis US Small Cap Equity ETF

0.04%

iShares Biotechnology ETF

0.04%

WisdomTree US SmallCap Fund

0.03%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.44%

iShares Neuroscience and Healthcare ETF

占比0.78%

Invesco NASDAQ Future Gen 200 ETF

占比0.7%

Federated Hermes MDT Small Cap Core ETF

占比0.62%

ALPS Medical Breakthroughs ETF

占比0.24%

ProShares Ultra Nasdaq Biotechnology

占比0.07%

Invesco Nasdaq Biotechnology ETF

占比0.06%

Avantis US Small Cap Equity ETF

占比0.04%

iShares Biotechnology ETF

占比0.04%

WisdomTree US SmallCap Fund

占比0.03%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Prothena Corporation PLC的前五大股东是谁？



Prothena Corporation PLC 的前五大股东如下：
Fidelity Management & Research Company LLC持有股份：7.90M，占总股份比例：14.68%。
Scully (William P)持有股份：5.35M，占总股份比例：9.94%。
Fennell (Todd W.)持有股份：4.35M，占总股份比例：8.08%。
BlackRock Institutional Trust Company, N.A.持有股份：3.12M，占总股份比例：5.80%。
The Vanguard Group, Inc.持有股份：2.17M，占总股份比例：4.03%。